Introduction {#s0005}
============

Late-onset hypogonadism (LOH), as defined by a serum total testosterone (TT) level of ⩽12 nmol/L, is diagnosed when declining testosterone concentrations in the ageing male cause unwanted symptoms such as erectile dysfunction (ED), obesity, lack of physical strength, and depressed mood [@b0005], [@b0010], [@b0015], [@b0020]. It is thought that almost 40% of men aged \>45 years are hypogonadal to some degree [@b0025].

Numerous studies have shown that testosterone levels are closely associated with both erectile function and obesity [@b0030], [@b0035], [@b0040]. In fact, the presence of visceral obesity can predict ED [@b0045] and weight loss improves erectile function and testosterone levels [@b0050], [@b0055]. Increasing evidence shows that testosterone can reduce both total and visceral body fat [@b0060], [@b0065], [@b0070], [@b0075], [@b0080], and is an effective treatment for ED, as measured by the International Index of Erectile Function (IIEF) questionnaire [@b0085], [@b0090], [@b0095].

Testosterone also maintains psychological features such as mood, vitality, libido and sexual interest, which contribute greatly to an overall sense of well-being and health-related quality of life (HRQoL). Consequently, in men with LOH there is an increase in symptoms such as dysphoria, low vigour and vitality, diminished libido and orgasm, irritability, poor cognitive function, and increased risk of depression [@b0100], [@b0105], [@b0110], [@b0115]. Associations have also been reported between both ED and depression [@b0120], and obesity and depression where obese patients at baseline were at an increased risk of depression at follow-up [@b0125]. Evidence that testosterone can effectively treat symptoms of depression comes from a randomised, placebo-controlled phase III trial in which 184 men with hypogonadism and metabolic syndrome were treated with testosterone undecanoate (TU) for 30 weeks. At the end of the trial period TU was found to have significantly improved depressive symptoms as measured by the Beck Depression Inventory (BDI-IA) [@b0130].

In men undergoing androgen-deprivation therapy for prostate cancer, mood disturbances, anxiety, fatigue, and lack of drive are observed [@b0135]. In a cohort of elderly hypogonadal men in the European Ageing Male Study, low testosterone levels were found to be associated with ED, low sexual desire, poor morning erections, fatigue, and depression [@b0140]. Thus, low testosterone-associated sexual dysfunction has a major impact on HRQoL and emotional well-being [@b0145], [@b0150], [@b0155].

Hypogonadal men undergoing testosterone replacement therapy (TRT) show improved parameters of well-being, bone density, muscle mass, physical strength, sexual function, and libido [@b0160]. In a study of men undergoing treatment with TU, there was an increase in libido, vigour and vitality, sleep quality, a reduction in waist circumference, and a decrease in severity of ED [@b0165]. Therefore, TRT in hypogonadal men may be a valuable tool to restore a physiological balance and achieve sexual pleasure as a component of well-being.

We hypothesised that TRT would improve both psychological and physical features that contribute to the long-term HRQoL in men with LOH.

Patients and methods {#s0010}
====================

From November 2004, 261 patients (mean age 58 years) diagnosed with LOH were treated with long-acting TU (Nebido®, Bayer Pharma, Berlin, Germany) in a prospective observational and longitudinal registry study. All patients gave their written informed consent to be included in the study, which was conducted according to ethical guidelines as formulated by the German 'Ärztekammer' (the German Medical Association) for observational studies and followed the principles outlined in the Helsinki Declaration of 1975, as revised in 1983. Men with a TT concentration of ⩽3.5 ng/mL (12 nmol/L) and documented symptoms of ED (Sexual Health Inventory for Men (SHIM) score of ⩽21) met the inclusion criteria. Men received i.m. injections of 1000 mg TU at day 1 (≈3 weeks after diagnosis), week 6 and every 3 months thereafter. Patients were entered into a cumulative registry database once they had received treatment for at least 1 year and followed for up to 5 years. The average treatment period was 4.25 years.

Assessment of outcome {#s0015}
---------------------

To assess the effect of long-term TU treatment, health quality indicators including the IPSS, the five-item version of the IIEF (IIEF-5), the Aging Males' Symptoms (AMS) scale, and the percentage of patients reporting joint and muscle pain were measured among the study population at baseline and at every subsequent visit. The means were then calculated and plotted over time in parallel with mean TT levels. A *P* \< 0.05 was considered to indicate statistical significance.

Results {#s0020}
=======

The mean IPSS measured at baseline was 10.35, which fell significantly within the first 3 months to 9.5 (*P* \< 0.05). This then decreased steadily over the remainder of the trial period and measured 7.22 after 63 months of TRT ([Fig. 1](#f0005){ref-type="fig"}).

The mean AMS score measured 54.27 at baseline and dropped dramatically to 37.42 within the first 3 months of the trial (*P* \< 0.05). The mean AMS score subsequently fell gradually to 28.66 by the end of the trial ([Fig. 2](#f0010){ref-type="fig"}).

At baseline the mean IIEF-5 score was 7.8 and increased to 13.31 over the first 3 months of the trial. By 9 months the mean IIEF-5 score was 17.55 and by the end of the trial was 21.96 ([Fig. 3](#f0015){ref-type="fig"}).

In all, 58% of patients reported joint pain at the beginning of the study, which dropped to 46% after 3 months of TRT, and dropped again to 22% after 9 months. By the end of the trial period at 63 months the percentage of patients reporting joint pain was just 1% ([Fig. 4](#f0020){ref-type="fig"}). Additionally, ≈60% of patients reported muscle pain at the start of the study, which dropped to ≈50% after 3 months and fell to a remarkably low level by the end of the study period.

TT levels increased over the first 3 months of the trial from 2.23 ng/mL (7.73 nmol/L) at baseline to 4.82 ng/mL (16.71 nmol/L) after 3 months, reflecting the changes seen in the health quality indicator scores. After 63 months of treatment, the mean TT levels were 5.39 ng/mL (18.69 nmol/L; [Figure 1](#f0005){ref-type="fig"}, [Figure 2](#f0010){ref-type="fig"}, [Figure 3](#f0015){ref-type="fig"}, [Figure 4](#f0020){ref-type="fig"}).

Discussion {#s0025}
==========

In the present prospective, observational and longitudinal study, we have shown that long-term treatment with TU in men with LOH results in a sustained improvement in health quality indicators including the IPSS, AMS, IIEF-5 scale, and reported joint and muscle pain, alongside increased TT levels, contributing to an improved, long-term HRQoL.

Our present findings confirm previous studies in which testosterone is shown to significantly improve sexual function and vitality, physical pain, general health, and the overall HRQoL in men with testosterone deficiency [@b0165], [@b0170], [@b0175], [@b0180], [@b0185], [@b0130], [@b0190]. Such studies provide evidence that testosterone improves the HRQoL in hypogonadal men [@b0195], [@b0200], [@b0205] and may explain the increase in physical activity that is often associated with TRT [@b0210].

In the present study, both the AMS score and IPSS fell significantly within the first 3 months of the trial. In a previous study, erectile function was found to improve as early as 3 weeks and the AMS score as early as 6 weeks after the initiation of TU treatment [@b0215]. However, it can take up to 12 months for maximum results [@b0215], showing clearly that long-term treatment with TU is required to achieve optimal effects. Thus, the duration of the present study, which allows time for the optimal effects of TU to be observed, provides a useful timescale to gain a thorough understanding of the time course of testosterone effects from which hypogonadal patients will benefit. The time course of IPSS improvement has been less well studied than other parameters of HRQoL. One study found a significant reduction in the IPSS at 3 months after commencing TU treatment [@b0220].

The results of several randomised, placebo-controlled trials observing the effect of TRT on symptoms of depression and HRQoL, as assessed by various subjective questionnaires, have produced mixed results; some found no effect of testosterone [@b0225], [@b0230], whereas other studies did find beneficial effects of testosterone on depression in men [@b0130], [@b0235]. However, these trials were short-term and therefore any indirect actions of testosterone to improve HRQoL, e.g. by improving the symptoms of metabolic syndrome and reducing obesity [@b0195], may not be apparent. As such, longer trials may be required for the positive effects of testosterone to materialise. Moreover, several studies included healthy men with TT levels of \>12.5 nmol/L [@b0225], [@b0240]. In the present study, the greatest improvements were seen within the first 3 months, an effect that was sustained throughout the remainder of the trial period, which lasted on average 4.25 years.

There are some potential limitations of the present study. The TT levels measured were trough levels, as blood samples were taken before the next TU injection, i.e. 3 months after the previous TU injection. Evidence from pharmacokinetic studies shows that TT levels between injections peak in the second week after injection [@b0245], [@b0250] and thus any dose-dependent effects seen may reflect this. A recent study demonstrated that in addition to testosterone, oestradiol plays an important role in the regulation of body fat and sexual function, thus a deficiency in this hormone may underlie a number of sequelae of male hypogonadism [@b0255]. Oestradiol levels were not measured in the present study and so this may be considered a further limitation of the study. One final limitation of the present study is the nature of the registry design. This single-centre, open-label study is not a randomised controlled study and therefore limits the scope of interpretation of the presented findings. However, our present findings were recently confirmed in a small placebo-controlled study in which 20 obese hypogonadal men with LUTS were treated for 5 years with TU [@b0260]. Although no changes in IPSS were seen, TT levels increased significantly with TRT [@b0260].

In conclusion, this prospective, observational and longitudinal analysis shows a clear improvement in the long-term HRQoL, both physically and psychologically, in men with LOH treated with TU.
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